Treatment with recombinant human erythropoietin in patients with aluminum overload and hyperparathyroidism.
In a European multicenter trial the weekly rates of increase in hematocrit and reticulocyte values were investigated in hemodialyzed patients with transfusion-dependent anemia treated with recombinant human erythropoietin (rHuEPO). Within a few months of therapy, the number of transfusion-dependent patients decreased to less than 5% of the group. Patients with aluminum overload indicated by elevated basal serum levels or elevated levels after a desferrioxamine challenge showed a significantly reduced response to rHuEPO. whereas in patients with elevated levels of parathyroid hormone a normal response to rHuEPO was found.
Grützmacher
P
P
II Medical Clinic, St. Markus Hospital, Frankfurt, FRG.
Ehmer
B
B
Limbach
J
J
Messinger
D
D
Kulbe
K D
KD
Scigalla
P
P
D000535:Aluminum / Q000097:blood*; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D001853:Bone Marrow / Q000187:drug effects; D004921:Erythropoietin / Q000627:therapeutic use*; D005060:Europe; D006403:Hematologic Tests; D006801:Humans; D006961:Hyperparathyroidism / Q000150:complications*; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis / Q000009:adverse effects*
D011994:Recombinant Proteins; D004921:Erythropoietin; D000535:Aluminum